The pharma sector is overcoming previous headwinds and is expected to perform better. Pricing pressure is reducing, new product launches are anticipated, and margin expansion is likely. The sector benefits from being defensive in volatile markets. Sectorally, all these headwinds that they had faced in the past are gradually going away for the sector to emerge better.